Camizestrant (Etcamah), SERENA-6
ESR1-mutated HR+/HER2- advanced breast cancer
Sponsor: AstraZeneca
- N/AEnrollment target
- N/ATrial sites
- N/ACountries
- TBDEst. completion
- N/ARegistry record
About this trial
Next-generation oral SERD, switched onto when an ESR1 resistance mutation emerges in circulating tumour DNA rather than when the scan changes.
Primary endpoints
- Progression-free survival
Latest update
September 2026
The FDA approved camizestrant with a CDK4/6 inhibitor for ESR1-mutated, HR-positive, HER2-negative advanced breast cancer, opening a ctDNA-guided treatment paradigm. The approval came despite a negative advisory committee vote on 30 April 2026 and a review-date extension announced on 27 May.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.